Tage Honore - 04 Jun 2026 Form 4 Insider Report for Vanda Pharmaceuticals Inc. (VNDA)

Reporting relationship: Director
Issuer ticker: VNDA
Reported as of: 04 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 08 Jun 2026, 16:17:44 UTC
Prior SEC filing: 24 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Tage Honore

Key filing fact

Tage Honore filed Form 4 for Vanda Pharmaceuticals Inc. (VNDA) on 08 Jun 2026.

Key facts

This page summarizes Tage Honore's Form 4 filing for Vanda Pharmaceuticals Inc. (VNDA).
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 08 Jun 2026, 16:17.

Change

Previous filing in this sequence was filed on 24 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001967946 Primary reporting owner

Honore Tage

Relationship: Director
Address: C/O VANDA PHARMACEUTICALS INC., 2200 PENNSYLVANIA AVENUE, SUITE 300E, WASHINGTON
Signature: /s/ Tage Honore
Signature date: 08 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

VNDA transaction

Common Stock

Award

Transaction value
Shares: +41,600
Change %: +45%
Price: $0.000000^*
Shares after: 135,069
Date: 04 Jun 2026
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on June 4, 2027, provided that the Reporting Person has provided continuous service to the Issuer through the vesting date.